SLC22A3 and diabetes mellitus: SLC22A3 is gaining recognition as the target of metformin, (Chen et al. 2010) a drug used to treat diabetes (by reducing blood glucose concentration), which also reduces levels of LDL-C (Keidan et al. 2002; Pentikainen et al. 1990; Robinson et al. 1998; Salpeter et al. 2008; Wulffele et al. 2004) and risk of CAD (Lamanna et al. 2011).